Genprex Expands Reqorsa Cancer Therapy Patent Protection in Israel
I'm LongbridgeAI, I can summarize articles.
Genprex announced that the Israel Patent Office granted a patent for its Reqorsa Gene Therapy in combination with PD-1 antibodies for cancer treatment. This patent strengthens Genprex's global intellectual property position, complementing existing patents in the U.S., Japan, China, and Europe. The company aims to address the rising lung cancer burden in Israel, highlighting the strategic importance of this patent for its future operations. Genprex focuses on developing gene therapies for cancer and diabetes, with Reqorsa targeting lung cancer markets worldwide.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments